Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
2,000

Quick answer

2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10947216

    Amide compounds and method for making and using

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10947310

    Fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10947507

    Platform for generating safe cell therapeutics

    The Regents of the University of California · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10947257

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10948495

    Methods and reagents for analyzing protein-protein interfaces

    Revolution Medicines, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10946096

    Nitrobenzaldehyde proton release for manipulation of cellular acidosis

    The Board of Regents of the University of Texas System · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10947317

    NaPi2b-targeted antibody-drug conjugates and methods of use thereof

    Mersana Therapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10947505

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10947312

    Human antibodies to GFRα3 and methods of making thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10947302

    Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them

    The Regents of the University of California · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10947277

    Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10947238

    Wee1 kinase inhibitors and methods of making and using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10947198

    Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents

    The Board of Regents for Oklahoma State University · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10946047

    Extracellular vesicles with enhanced potency

    United Therapeutics Corporation · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10946009

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10947306

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10945988

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10947177

    Compounds and methods for delivery of prostacyclin analogs

    United Therapeutics Corporation · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10947295

    Heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10947180

    Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists

    VTV THERAPEUTICS LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10947254

    Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10946107

    Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10946065

    Methods of treating fungal infections

    United States of America as represented by the Secretary of the Air Force · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. EP 3791896

    KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS

    ASTELLAS PHARMA INC [JP] · Granted Wed Mar 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Mar 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. WO 2021048135

    COMBINAISONS PHARMACEUTIQUES COMPRENANT UN FURAZANOBENZIMIDAZOLE ET UN AGONISTE DE CD40 POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES NÉOPLASIQUES

    BASILEA PHARM INT AG [CH] · Granted Thu Mar 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10954192

    Pyrrolomycins and methods of using the same

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10952997

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10953028

    Method of treating heterotopic ossification

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10952970

    Use of vitelline protein B as a microencapsulating additive

    The Regents of the University of California · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10953000

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10954529

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10954498

    Modified cascade ribonucleoproteins and uses thereof

    Caribou Biosciences, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10954259

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10954198

    Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

    United Kingdom Research and Innovation · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10953209

    Treating tumors using TTFields combined with a PARP inhibitor

    The Board of Regents of the University of Texas System · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10953047

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10953040

    Methods of treating bacterial infections with penam β-lactam antibiotics and branched poly(ethylenimine)

    The Board of Regents of the University of Oklahoma · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10952996

    ALK5 inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10952978

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10952980

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10953018

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10953110

    Dual emissive metal nanoparticles as ratiometric pH indicators

    The Board of Regents of the University of Texas System · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10953026

    N-acetyl mannosammine as a therapeutic agent

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10952993

    Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

    VTV THERAPEUTICS LLC · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10953003

    Methods for treating cancer

    X4 Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10953031

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.